Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07 March 2023 - 8:05AM
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global
biopharmaceutical company and leader in complement, today announced
that the company approved the grant of equity awards to 6 new
employees with a grant date of March 1, 2023, as equity inducement
awards outside of the company's 2017 Stock Incentive Plan (but
under the terms of the 2022 Inducement Stock Incentive Plan) and
material to the employees’ acceptance of employment with the
company. The equity awards were approved in accordance with Nasdaq
Listing Rule 5635(c)(4).
The employees received options to purchase 19,495 restricted
stock units (RSUs). Each RSU will vest as to 25% of the shares
underlying the RSU award on the first anniversary of the grant date
and as to an additional 25% of the shares underlying the RSU award
annually thereafter, subject to each such employee's continued
employment on each vesting date.
About ApellisApellis Pharmaceuticals, Inc. is a
global biopharmaceutical company that is committed to leveraging
courageous science, creativity, and compassion to deliver
life-changing therapies. Leaders in complement, we ushered in the
first new class of complement medicine in 15 years with the
approval of the first and only targeted C3 therapy. We are
advancing this science to continually develop transformative
medicines for people living with rare, retinal, and neurological
diseases. For more information, please
visit http://apellis.com or follow us
on Twitter and LinkedIn.
Apellis Forward-Looking StatementStatements in
this press release about future expectations, plans and prospects,
as well as any other statements regarding matters that are not
historical facts, may constitute “forward-looking statements”
within the meaning of The Private Securities Litigation Reform Act
of 1995. The words “anticipate,” “believe,” “continue,” “could,”
“estimate,” “expect,” “intend,” “may,” “plan,” “potential,”
“predict,” “project,” “should,” “target,” “will,” “would” and
similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words. Actual results may differ materially from
those indicated by such forward-looking statements as a result of
various important factors, as discussed in the “Risk Factors”
section of Apellis’ Annual Report on Form 10-K with the Securities
and Exchange Commission on February 21, 2023 and the risks
described in other filings that Apellis may make with the
Securities and Exchange Commission. Any forward-looking statements
contained in this press release speak only as of the date hereof,
and Apellis specifically disclaims any obligation to update any
forward-looking statement, whether as a result of new information,
future events or otherwise.
Investor Contact:Meredith
Kayameredith.kaya@apellis.com617.599.8178
Apellis Pharmaceuticals (NASDAQ:APLS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Apellis Pharmaceuticals (NASDAQ:APLS)
Historical Stock Chart
From Apr 2023 to Apr 2024